The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

FROM eggy burps to stomach-churning nausea, there appears to be an endless list of side effects linked to Ozempic-like jabs. But now, experts are getting candid on a fat jab complication that ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. WEIGHT-LOSS MEDICATIONS MAY ALSO BENEFIT COMMON ...

"This study allowed us to do a direct comparison ... to choose a weight-loss medication that matches the patient’s personal goals and health status. "Both Wegovy and Zepbound have demonstrated ...